Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald F Watts

Showing results (441-450 of 706) with videos related to

Pageof 71
Sort By:
Clinical Science (London, England : 1979)|September 29, 2004
Cardiovascular risk factors and endothelial dysfunctionAnthony S Wierzbicki, Philip J Chowienczyk, John R Cockcroft, et al.
Journal of Lipid Research|June 23, 2009
Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-IIIDoris T Chan, Gursharan K Dogra, Ashley B Irish, et al.
Metabolism: Clinical and Experimental|April 3, 2020
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)Gerald F Watts, Dick C Chan, Jing Pang, et al.
Diabetes Care|August 5, 2009
Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndromeDick C Chan, Gerald F Watts, Esther M M Ooi, et al.
Atherosclerosis|May 13, 2014
Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitionerDamon A Bell, Amanda J Hooper, Glenn Edwards, et al.
Asia Pacific Journal of Clinical Nutrition|November 29, 2007
Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndromeEsther M M Ooi, Gerald F Watts, P Hugh R Barrett, et al.
Clinical Science (London, England : 1979)|May 17, 2006
Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndromeGerald F Watts, Juying Ji, Dick C Chan, et al.
Prostaglandins & Other Lipid Mediators|March 27, 2018
The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney diseaseAnne E Barden, Sujata Shinde, Valerie Burke, et al.
Pharmacoeconomics|January 24, 2024
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic ReviewClara Marquina, Jedidiah I Morton, Melanie Lloyd, et al.
Journal of the American Heart Association|March 17, 2020
Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery DiseaseJonathan Golledge, Sophie Rowbotham, Ramesh Velu, et al.
Pageof 71

Showing results (441-450 of 706) with videos related to

Sort By:
Pageof 71
Clinical Science (London, England : 1979)|September 29, 2004
Cardiovascular risk factors and endothelial dysfunctionAnthony S Wierzbicki, Philip J Chowienczyk, John R Cockcroft, et al.
Journal of Lipid Research|June 23, 2009
Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-IIIDoris T Chan, Gursharan K Dogra, Ashley B Irish, et al.
Metabolism: Clinical and Experimental|April 3, 2020
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)Gerald F Watts, Dick C Chan, Jing Pang, et al.
Diabetes Care|August 5, 2009
Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndromeDick C Chan, Gerald F Watts, Esther M M Ooi, et al.
Atherosclerosis|May 13, 2014
Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitionerDamon A Bell, Amanda J Hooper, Glenn Edwards, et al.
Asia Pacific Journal of Clinical Nutrition|November 29, 2007
Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndromeEsther M M Ooi, Gerald F Watts, P Hugh R Barrett, et al.
Clinical Science (London, England : 1979)|May 17, 2006
Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndromeGerald F Watts, Juying Ji, Dick C Chan, et al.
Prostaglandins & Other Lipid Mediators|March 27, 2018
The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney diseaseAnne E Barden, Sujata Shinde, Valerie Burke, et al.
Pharmacoeconomics|January 24, 2024
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic ReviewClara Marquina, Jedidiah I Morton, Melanie Lloyd, et al.
Journal of the American Heart Association|March 17, 2020
Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery DiseaseJonathan Golledge, Sophie Rowbotham, Ramesh Velu, et al.
Pageof 71